ERBB2 and breast cancer: Lee et al23 showed that, compared with the current recommendation of AHT within 12 months of diagnosis, the initiation of AHT at 12 to 24 months after diagnosis may not be related to reduced survival of patients with stage II and III, HR-positive, ERBB2-negative breast cancer who received chemotherapy.